Analgesic Effect of Dizocine Combined with Ropivacaine on Recurrent Neuropathic Pain in Peripheral Nerve Compression Rats

Xiao, Zhang; Chu, Chunqin; Ma, Chengtai; Sun, Jian; Liu, Zhenfang

doi:10.1159/000503903

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected dezocine or sufentanil, as an opiate for anesthesia and analgesia options for breast cancer patients, respectively, with the regimen and the dosage used according to the references or guidelines and the Chinese expert consensus. 41,42 Th1 Cells and Th2 Cells Measurement A 2 mL peripheral blood sample was collected from the elbow vein before surgery and 2, 12, 24, and 48 hours after surgery in an anticoagulant tube containing sodium heparin.…”

Section: Postoperative Analgesiamentioning

confidence: 99%

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

Hu¹,

Liu²,

Wu³

et al. 2021

DDDT

View full text Add to dashboard Cite

Background: It is very important for breast cancer patients undergoing surgery to choose an opioid that has little effect on the immune system. The aim of this study is to compare the effects of dezocine or sufentanil on postoperative pain and Th1/Th2 balance in patients undergoing breast cancer surgery. Methods: Data from 92 breast cancer patients from January 2019 to July 2020 at Foshan Second People's Hospital (Guangdong, China) were analyzed. Sufentanil (SF) was used in group SF (n = 44) and dezocine (DE) in group DE (n = 48). The Visual Analog Scale (VAS) scores were assessed, and the percentages of Th1 cells and Th2 cells in peripheral blood were detected before anesthesia and at 2, 12, 24, and 48 hours after surgery. Results: There was no significant difference in the VAS scores between the two groups at 2, 24, and 48 hours after surgery (P > 0.05). The VAS scores at 12 hours after surgery in group DE were significantly lower than those in group SF with a statistically significant difference (P < 0.05). The percentage of Th1 cells in group DE at 2, 12, 24, and 48 hours after surgery was significantly lower than that in group SF (P < 0.05). The percentage of Th2 cells in group DE at 2, 12, 24, and 48 hours after surgery was significantly lower than that in group SF (P < 0.05). The Th1/Th2 ratio at 2, 12, 24, and 48 hours after surgery was significantly higher in group DE than that in group SF (P < 0.05). Conclusion: Dezocine for anesthesia induction and postoperative analgesia can maintain the balance of Th1/Th2 more stable than, with the same analgesia efficacy as, sufentanil during the early postoperative period in breast cancer patients undergoing surgery.

show abstract

Section: Postoperative Analgesiamentioning

confidence: 99%

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

Hu¹,

Liu²,

Wu³

et al. 2021

DDDT

View full text Add to dashboard Cite

show abstract

“…Dezocine, an organic compound, is an κ agonist and a µ receptor antagonist. It is mainly used for postoperative analgesia and pain caused by visceral and cancer [18]. Dezocine is a powerful opioid analgesic [19]; It can relieve postoperative pain, and its analgesic intensity is comparable to morphine [20].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, the antitumor effects and mechanisms of anesthetics are being unraveled [18]. Research results have proved that anesthetics can affect the apoptosis, proliferation, metastasis and DNA demethylation of oncogenes in some tumor cells [6].…”

Section: Discussionmentioning

confidence: 99%

Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Endometrial cancer (EC) includes several epithelial malignancies existed in the endometrium tissues. To improve the prognosis of EC, it is greatly needed to find new drugs. Dezocine, a organic compound, is an κ agonist and a µ receptor antagonist, is used in clinical anesthesia after cancer surgery with few side effects, and its anti-tumor effects have also been demonstrated in several tumors. However, the effects of Dezocine on EC progression have not been elusidated. Herein, we investigated the role of Dezocine in EC cell functions. Through a series of cellular assays, such as cell counting kit-8 (CCK-8), flow cytometry (FCM), transwell assays, we found that Dezocine suppressed the EC cell proliferation, and stimulated EC cell apoptosis in vitro. Furthermore, results revealed Dezocine restrained the motility, including migration and invasion of EC cells. Mechanically, Dezocine suppressed the Akt (protein kinase B, PKB)/mammalian target of rapamycin (mTOR) pathway in EC cells, thereby suppressing EC cell proliferation as well as migration in vitro. In conclusion, Dezocine inhibits proliferation as well as migration of EC in vitro.

show abstract

Dezocine as a potent analgesic: overview of its pharmacological characterization

Jiang

et al. 2021

Acta Pharmacol Sin

View full text Add to dashboard Cite

Dezocine, a synthetic opioid, introduced in 1970s as an analgesic, was redeveloped for relieving moderate to severe pain by Yangtze River Pharmaceutical Group in China in 2009. To date, dezocine occupies 45% of China's opioid analgesic market. Along with dezocine being a dominated painkiller, a certain amount of research was conducted to elucidate dezocine's action. In this review we summarize the current knowledge on the receptor, preclinical and clinical pharmacology of dezocine. Briefly, preclinical data show that dezocine is effective under varying pain conditions, particularly chronic neuropathic pain and cancer pain, through activation of opioid receptors, and inhibition of norepinephrine reuptake. Clinical data establish the effectiveness of dezocine either as a primary analgesic for postoperative pain management or a supplement for balanced analgesia. The receptor profile of dezocine is different from known pure μ agonists, and allows it to be used in combination with other opioids for additivity in efficacy or lower incidence of adverse effects.

show abstract

Analgesic Effect of Dizocine Combined with Ropivacaine on Recurrent Neuropathic Pain in Peripheral Nerve Compression Rats

Cited by 3 publications

References 20 publications

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

Dezocine inhibits proliferation as well as migration of endometrial carcinoma in vitro

Dezocine as a potent analgesic: overview of its pharmacological characterization

Contact Info

Product

Resources

About